DOCSLIB.ORG

Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need GBI Research Report Guidance GBI Research Report Guidance The second chapter provides an introduction to the GI therapeutic indications of IBS, UC and CD, including epidemiology, symptoms, etiology, pathophysiology, diagnosis, disease classification and determination of disease severity, and treatment. The third chapter provides an overview of the product profiles for six key marketed products for the treatment of IBS, UC, and CD. The fourth chapter analyses the IBS, UC, and CD pipeline, providing details of, among other parameters, drug distribution by phase, molecule type, and mechanism of action. The chapter also profiles three promising drug candidates in the pipeline. The fifth chapter provides a market forecast to 2019 for the APAC markets of Australia, India, China, and Japan, and includes prevalence population, Annual Cost of Therapy (ACoT) and market size forecast, along with details of drivers and barriers affecting the GI market. Chapter six provides a strategic consolidation analysis, including details of major co-development and licensing deals. © GBI Research. This is a licensed product and is not to be photocopied GBIHC320MR / Published JAN 2014 Page 2 Executive Summary The gastrointestinal market Executive Summary is expected to grow in Asia- Gastrointestinal Therapeutics Market in Asia-Pacific to Grow by XX% to Reach $XX Billion in 2019 Pacific region due to new product launches The Gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC), and Crohn’s Disease (CD) in the Asia-Pacific (APAC) region, comprising Australia, India, China, and Japan, had an estimated value of $XXm in 2012, which is expected to increase at a Compound Annual Growth Rate (CAGR) of XX% during the forecast period to reach $XXm in 2019. India registers the fastest growth rate at a CAGR of XX%, followed by China, which is expected to register growth at a CAGR of XX%. Japan is the market leader in the APAC region, accounting for $XXm in 2012, equivalent to almost XX% of the total GI market in the region. The market is expected to grow due to new product launches and substantial growth in the size of the diseased population during the forecast period. Gastrointestinal Therapeutics Market, Asia-Pacific, Market Size ($m), 2012–2019 Revenue Revenue ($m) 2012 2019 Australia India China Japan Source: GBI Research Proprietary Products Database [accessed October 16, 2013] © GBI Research. This is a licensed product and is not to be photocopied GBIHC320MR / Published JAN 2014 Page 3 Table of Contents 1 Table of Contents 1 Table of Contents ................................................................................................................................. 6 1.1 List of Tables ............................................................................................................................. 9 1.2 List of Figures...........................................................................................................................10 2 Gastrointestinal Therapeutics in Asia-Pacific Market – Introduction .....................................................11 2.1 Irritable Bowel Syndrome .........................................................................................................11 2.1.1 Classification ....................................................................................................................11 2.1.2 Symptoms ........................................................................................................................11 2.1.3 Etiology ...........................................................................................................................11 2.1.4 Pathophysiology...............................................................................................................12 2.1.5 Diagnosis .........................................................................................................................12 2.1.6 Epidemiology ...................................................................................................................14 2.1.7 Prognosis .........................................................................................................................14 2.1.8 Treatment Options ...........................................................................................................14 2.2 Ulcerative Colitis ......................................................................................................................15 2.2.1 Classification ....................................................................................................................15 2.2.2 Symptoms ........................................................................................................................17 2.2.3 Etiology ...........................................................................................................................17 2.2.4 Pathophysiology...............................................................................................................17 2.2.5 Diagnosis .........................................................................................................................18 2.2.6 Epidemiology ...................................................................................................................19 2.2.7 Prognosis .........................................................................................................................19 2.2.8 Treatment Options ...........................................................................................................19 2.3 Crohn’s Disease .......................................................................................................................21 2.3.1 Classification ....................................................................................................................21 2.3.2 Symptoms ........................................................................................................................22 2.3.3 Etiology ...........................................................................................................................22 2.3.4 Pathophysiology...............................................................................................................23 2.3.5 Diagnosis .........................................................................................................................23 2.3.6 Epidemiology ...................................................................................................................24 2.3.7 Prognosis .........................................................................................................................24 2.3.8 Treatment Options ...........................................................................................................25 3 Gastrointestinal Therapeutics in Asia-Pacific Market – Marketed Products (Global) ..............................26 3.1 Irritable Bowel Syndrome .........................................................................................................26 3.2 Ulcerative Colitis ......................................................................................................................26 3.3 Crohn’s Disease .......................................................................................................................26 3.4 Key Marketed Products ............................................................................................................27 3.4.1 Amitiza ............................................................................................................................27 3.4.2 Humira ............................................................................................................................28 3.4.3 Remicade .........................................................................................................................29 3.4.4 Simponi ...........................................................................................................................30 3.4.5 Cimzia..............................................................................................................................31 3.4.6 Tysabri .............................................................................................................................32 4 Gastrointestinal Therapeutics in Asia-Pacific Market – Pipeline Analysis ...............................................34 4.1 Irritable Bowel Syndrome .........................................................................................................34 4.1.1 Overall Pipeline ................................................................................................................34 4.1.2 Pipeline Analysis by Molecule Type ...................................................................................36 4.1.3 Pipeline Analysis by Mechanism of Action .........................................................................37 4.2 Ulcerative Colitis Pipeline .........................................................................................................39 4.2.1 Overall Pipeline ................................................................................................................39 4.2.2 Pipeline Analysis by Molecule Type ...................................................................................41
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Bristol-Myers Squibb Company – Product Pipeline Review – 2014
    Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Reference Code: GMDHC05245CDB Publication Date: JUN 2014 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Bristol-Myers Squibb Company – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 12 List of Figures ...................................................................................................................................................................... 12 Bristol-Myers Squibb Company Snapshot.................................................................................................................................. 13 Bristol-Myers Squibb Company Overview ............................................................................................................................. 13 Key Information ................................................................................................................................................................... 13 Key Facts ...........................................................................................................................................................................
    [Show full text]
  • PDF File of an Unedited Manuscript That Has Been Accepted for Publication
    Accepted Manuscript Efficacy of Ustekinumab in Inducing Endoscopic Healing in Patients with Crohn’s Disease Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Jean-Frederic Colombel, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Omoniyi J. Adedokun, Brian G. Feagan, William J. Sandborn PII: S0016-5085(18)34655-9 DOI: 10.1053/j.gastro.2018.06.035 Reference: YGAST 61941 To appear in: Gastroenterology Accepted Date: 8 June 2018 Please cite this article as: Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel J-F, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ, Efficacy of Ustekinumab in Inducing Endoscopic Healing in Patients with Crohn’s Disease, Gastroenterology (2018), doi: 10.1053/j.gastro.2018.06.035. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Target Journal: Gastroenterology Rutgeerts P Efficacy of Ustekinumab in Inducing Endoscopic Healing in Patients with Crohn’s Disease Short title: Ustekinumab for Endoscopic Healing in Patients with Crohn’s Disease Paul Rutgeerts,1 Christopher Gasink, 2 Daphne Chan, 2 Yinghua Lang, 2 Paul Pollack, 2 Jean- Frederic Colombel, 3 Douglas C Wolf, 4 Douglas Jacobstein, 2 Jewel Johanns, 2 Philippe Szapary,2 Omoniyi J Adedokun, 2 Brian G Feagan, 5 William J Sandborn 6 1 University Hospital Gasthuisberg, Leuven, Belgium; 2Janssen Research &Development, LLC, Spring House, PA; 3The Dr.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • 211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
    211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease The impact of biological interventions on health-related quality of life in adults with Crohn's disease Protocol information Review type: Intervention Review number: 211 Authors Mirjana Stanic Benic1, Vanja Giljaca2, Vera Vlahovic-Palcevski1 1Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia 2Directorate of Surgery, Department of Gastroenterology, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, UK Citation example: Stanic Benic M, Giljaca V, Vlahovic-Palcevski V. The impact of biological interventions on health- related quality of life in adults with Crohn's disease. Cochrane Database of Systematic Reviews , Issue . Art. No.: . DOI: . Contact person Mirjana Stanic Benic resident in clinical pharmacology and toxicology Department of Clinical Pharmacology Clinical Hospital Centre Rijeka Krešimirova 42 Rijeka 51000 Croatia E-mail: [email protected] Dates Assessed as Up-to-date:Not provided Date of Search: Not provided Next Stage Expected: 28 February 2019 Protocol First Published:Not specified Review First Published: Not specified Last Citation Issue: Not specified What's new Date Event Description History Date Event Description Abstract Background Objectives Search methods Selection criteria Data collection and analysis Main results Authors' conclusions Plain language summary [Summary title] [Summary text] Background Description of the condition 1 / 20 211 The impact of biological interventions on health-related quality of life in adults with Crohn's disease Crohn’s disease (CD) is a relapsing-remitting transmural inflammatory bowel disease (IBD) that may involve any part of the gastrointestinal tract from mouth to anus as well as cause extraintestinal manifestations (skin lesions, arthritis).
    [Show full text]